105 related articles for article (PubMed ID: 19934951)
1. The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas.
Komotar RJ; Starke RM; Sisti MB; Connolly ES
Neurosurgery; 2009 Dec; 65(6):N12. PubMed ID: 19934951
[No Abstract] [Full Text] [Related]
2. Hearing improvement after bevacizumab for neurofibromatosis type 2.
Diao JS; Xia WS; Guo SZ
N Engl J Med; 2009 Oct; 361(18):1810; author reply 1810-1. PubMed ID: 19877310
[No Abstract] [Full Text] [Related]
3. Hearing improvement after bevacizumab for neurofibromatosis type 2.
Guntinas-Lichius O
N Engl J Med; 2009 Oct; 361(18):1809-10; author reply 1810-1. PubMed ID: 19864683
[No Abstract] [Full Text] [Related]
4. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Eminowicz GK; Raman R; Conibear J; Plowman PN
J Laryngol Otol; 2012 Jan; 126(1):79-82. PubMed ID: 22004800
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
8. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
Mautner VF; Nguyen R; Knecht R; Bokemeyer C
Ann Oncol; 2010 Nov; 21(11):2294-2295. PubMed ID: 20860987
[No Abstract] [Full Text] [Related]
9. The role of vascular endothelial growth factor and vascular stability in diseases of the ear.
London NR; Gurgel RK
Laryngoscope; 2014 Aug; 124(8):E340-6. PubMed ID: 24347479
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities.
Sverak P; Adams ME; Haines SJ; Levine SC; Nascene D; Sommer K; Dusenbery K; Huang TC; Moertel C
Otolaryngol Head Neck Surg; 2019 Mar; 160(3):526-532. PubMed ID: 30373466
[TBL] [Abstract][Full Text] [Related]
11. Natural history of hearing deterioration in intracanalicular vestibular schwannoma.
Pennings RJ; Morris DP; Clarke L; Allen S; Walling S; Bance ML
Neurosurgery; 2011 Jan; 68(1):68-77. PubMed ID: 21099722
[TBL] [Abstract][Full Text] [Related]
12. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.
Grover S; Gupta S; Sharma R; Brar VS; Chalam KV
Br J Ophthalmol; 2009 Feb; 93(2):273-4. PubMed ID: 18617542
[No Abstract] [Full Text] [Related]
13. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
14. Consequences to hearing during the conservative management of vestibular schwannomas.
Walsh RM; Bath AP; Bance ML; Keller A; Rutka JA
Laryngoscope; 2000 Feb; 110(2 Pt 1):250-5. PubMed ID: 10680925
[TBL] [Abstract][Full Text] [Related]
15. Body fatness and bevacizumab-based therapy in metastatic colorectal cancer.
Renehan AG
Gut; 2010 Mar; 59(3):289-90. PubMed ID: 20207633
[No Abstract] [Full Text] [Related]
16. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-based therapy for advanced small bowel adenocarcinoma.
Tsang H; Yau T; Khong PL; Epstein RJ
Gut; 2008 Nov; 57(11):1631-2. PubMed ID: 18941013
[No Abstract] [Full Text] [Related]
18. [Unusual clinical presentations of vestibular schwannomas].
Coca Pelaz A; Rodrigo JP; Llorente JL; Gómez JR; Suárez C
Acta Otorrinolaringol Esp; 2008 Apr; 59(4):187-9. PubMed ID: 18447978
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab: a new hope?
Madhusudhana KC; Newsom RS
Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
[No Abstract] [Full Text] [Related]
20. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
